Get the Stockscreener App
2.16
0.93%
0.02
After Hours:
2.16
Adlai Nortye Ltd Adr stock is traded at $2.16, with a volume of 2,255.
It is up +0.93% in the last 24 hours and down -16.28% over the past month.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
See More
Previous Close:
$2.14
Open:
$2.1146
24h Volume:
2,255
Relative Volume:
0.16
Market Cap:
$79.70M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-0.8572
EPS:
-2.5197
Net Cash Flow:
-
1W Performance:
-5.68%
1M Performance:
-16.28%
6M Performance:
-40.17%
1Y Performance:
-75.74%
1-Day Range:
$2.11
$2.16
1-Week Range:
$2.1001
$2.441
52-Week Range:
$1.85
$17.48
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
2.16 | 79.70M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Stock (ANL) Latest News
Trump Announces Nomination of Howard Lutnick to Serve as US Commerce Secretary, to Run Office of US Trade Representative - AASTOCKS.com
Adlai Nortye shares hold Buy rating by H.C. Wainwright on oncology programs - Investing.com
Adlai Nortye stock strengthened by oncology trial results, H.C. Wainwright keeps at Buy list - Investing.com
ANL stock touches 52-week low at $1.85 amid sharp annual decline - Investing.com
ANL stock touches 52-week low at $1.85 amid sharp annual decline By Investing.com - Investing.com South Africa
Adlai Nortye stock plunges to 52-week low of $1.89 - Investing.com
Adlai Nortye stock plunges to 52-week low of $1.89 By Investing.com - Investing.com Canada
Adlai Nortye Ltd. Sponsored ADR (ANL) Loses -33.06% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
H.C. Wainwright sees upside in Adlai Nortye stock amid robust oncology pipeline - Investing.com
Adlai Nortye Reports Strong 2024 Mid-Year Results - TipRanks
Adlai Nortye releases unaudited H1 2024 results, adds new director - Investing.com
Adlai Nortye Announces Executive Leadership Transition - TipRanks
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Markets Insider
symbol__ Stock Quote Price and Forecast - CNN
Adlai Nortye (ANL) Stock Price, News & Analysis - MarketBeat
IPO Update: Adlai Nortye Readies $72 Million U.S. IPO (Pending:ANL) - Seeking Alpha
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Adlai Nortye Ltd Adr Stock (ANL) Financials Data
There is no financial data for Adlai Nortye Ltd Adr (ANL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):